ATTACHMENT A

Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1-20. (Canceled)
- 22. (Previously presented) An isolated human serum albumin having an amino acid sequence that begins with Ala-His-Lys-Ser-Glu (SEQ ID NO: 1) at its N-terminal end.
- 23. (Previously presented) A pharmaceutical or cosmetic composition comprising the serum albumin according to claim 22 and a physiologically acceptable vehicle, carrier or excipient.
- 24. (Previously presented) An isolated human serum albumin according to claim 22 that is produced through recombinant means.
- 25. (Previously presented) An isolated human serum albumin according to claim 22 that is produced using a transgenic plant.
- 26. (Previously presented) An isolated human serum albumin according to claim 22 that is produced through physical or chemical means.
 - 27. (Canceled)
- 28. (Previously presented) An isolated human serum albumin having an amino acid sequence that begins with Lys-Ser-Glu at its N-terminal end.
- 29. (Previously presented) An isolated human serum albumin having an amino acid sequence that begins with Glu-Ala-Glu-Phe-Asp-Ala-His (SEQ ID NO: 5) at its N-terminal end.
 - 30. (Canceled)